Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

60%

3 trials in Phase 3/4

Results Transparency

75%

3 of 4 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 4

3(60.0%)

Phase 2

1(20.0%)

Phase 1

1(20.0%)

5Total

Phase 4(3)

Phase 2(1)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT00152451Phase 2Completed

Study With Seletracetam (Ucb 44212) in Adult Subjects (18 to 65 Years) With Partial Onset Seizures

Role: lead

NCT00160680Phase 4Completed

ATAREAL (Antihistamine Treatment for Allergic Rhinitis in Real Life)

Role: lead

NCT00295022Phase 4Completed

Compare the Efficacy of Levocetirizine and Montelukast to Placebo in Reducing Seasonal Allergic Rhinitis (SAR) Symptoms in Ragweed Sensitive Subjects

Role: lead

NCT02606682Phase 1Completed

Phase 1 Study of NPT200-11 in Healthy Subjects

Role: collaborator

NCT01883011Phase 4Terminated

A Study to Evaluate the Efficacy and Safety of Piracetam on Aphasia After Acute Ischemic Cerebral Artery Stroke

Role: lead

All 5 trials loaded